The Prevalence of Neuropathic Pain in Multiple Sclerosis-A Systematic Review and Meta-Analysis Using the NeuPSIG Algorithm.

Eur J PainSep 1, 2026
Clinical ResearchNeurologyOpen access

Rasmus C Jungersen, Victor K Baccaro, Lars G Hvid et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis estimated the prevalence of neuropathic pain in multiple sclerosis (MS) using the NeuPSIG algorithm. Among 32 eligible studies, the overall prevalence of neuropathic pain was found to be 22.3% (95% CI: 17.3; 27.3). The study also reported similar prevalence rates across diagnostic certainty levels: possible (22.0%), probable (23.7%), and definite (23.4%) neuropathic pain.

Key findings

  • Overall prevalence of neuropathic pain in MS was 22.3% (95% CI: 17.3; 27.3).
  • Prevalence of possible neuropathic pain was 22.0% (95% CI: 16.0; 28.0).
  • Prevalence of probable neuropathic pain was 23.7% (95% CI: 19.4; 28.0).
  • Prevalence of definite neuropathic pain was 23.4% (95% CI: 1.11; 35.8).

Why it matters

Understanding the prevalence of neuropathic pain in MS is crucial for clinicians to improve diagnosis and management strategies. The findings highlight the need for accurate diagnostic classifications to guide treatment and research.

Source

PubMed · PMID 42678174Free full text on PubMed Central

Published in Eur J Pain. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.